Wednesday, December 31, 2014 5:17:55 PM
Shares of Cytokinetics, Inc. (NASDAQ: CYTK) surged 16 percent Wednesday following Roth Capital raising its price target on the company from $13 to $18.
The analyst note cited four facets for its strengthened investment case:
1) "CYTK has shown its prowess in attracting significant partnerships in the form of both Amgen and Astellas,"
2) "each of these partners have approximately the same equity stake in CYTK as well,"
3) "a regulatory path forward for tirasemtiv for ALS is expected in the near term and, importantly,"
4) "the company has a strong financial footing with 2-3 years of cash on hand with the recently expanded Astellas collaboration (~$150 million pro forma cash)."
Analyst Joseph Pantginis concluded, “While the final trial design for a pivotal study has not yet been agreed upon with the FDA and EMEA, the trial design will likely contain and adaptive design as well as important interim analyses. This should allow CYTK to "titrate" their spending on the ALS study on an "as needed basis".”
Cytokinetics recently traded at $8.03, up 16.4 percent.
Latest Ratings for CYTK
Date Firm Action From To
Nov 2014 MLV & Co. Upgrades Hold Buy
May 2014 Leerink Swann Maintains Outperform
Apr 2014 Piper Jaffray Downgrades Overweight Neutral
View More Analyst Ratings for CYTK
View the Latest Analyst Ratings
http://finance.yahoo.com/news/cytokinetics-surges-amid-roth-capital-165217416.html
Recent CYTK News
- Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting • GlobeNewswire Inc. • 09/19/2024 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 08:15:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 08:10:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/17/2024 08:03:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/16/2024 08:29:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/09/2024 08:12:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/09/2024 08:05:54 PM
- Cytokinetics Announces Data From Phase 1 Study of CK-4021586 • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting • GlobeNewswire Inc. • 09/05/2024 08:00:00 PM
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 09/04/2024 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 09:14:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 09:09:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 09:06:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 08:08:03 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/03/2024 08:07:05 PM
- Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024 • GlobeNewswire Inc. • 09/01/2024 08:27:00 AM
- Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024 • GlobeNewswire Inc. • 09/01/2024 07:51:00 AM
- Cytokinetics to Participate in September Investor Conferences • GlobeNewswire Inc. • 08/29/2024 08:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/26/2024 08:14:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2024 08:00:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/22/2024 08:00:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/20/2024 08:08:50 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 08/19/2024 08:07:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 08:00:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 08:00:08 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM